Friday 21 June 2024

LTR Pharma (ASX:LTP) has listed on the ASX

LTR Pharma (ASX:LTP) has listed on the ASX with a ticker code of LTP. The company is a clinical stage biopharmaceutical company and pioneering a novel intranasal technology – SPONTAN® – designed to treat erectile dysfunction in 10 minutes or less. LTR Pharma says the benefit of its business model is a significantly reduced time to approval and lower cost, even when compared with traditional drug repurposing strategies. The global erectile dysfunction market is expected to generate revenue of more than $7 billion US dollars by the end of 2026 | Investor presentation: #LTP #ASX #ASXstocks #stocks #ASXIPO ##LTRPharma #ED #erectiledysfunction #shorts

Free stock updates

Subscribe to receive the latest stock news, CEO interviews, expert insights, events and offers directly into your inbox